This report was first published by Endpoints News. To see the original version, click here
A high-dose version of Innovent Biologics’ obesity drug led to patients with moderate-to-severe disease losing 18.6% of their body weight in about a year and two months, according to data from a late-stage China-based trial.
The drug, which is known generically as mazdutide, is already approved in China for both obesity and type 2 diabetes under the name Xinermei. It is a dual agonist of GLP-1 and glucagon, the first such drug to gain approval anywhere in the world.
您已阅读21%（559字），剩余79%（2087字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。